Michalski J - Search Results

1

Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377.

Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Spratt DE, et al. Among authors: michalski j. Int J Radiat Oncol Biol Phys. 2024 Dec 1;120(5):1461. doi: 10.1016/j.ijrobp.2024.08.044. Epub 2024 Sep 23. Int J Radiat Oncol Biol Phys. 2024. PMID: 39320298 Free article. No abstract available.

2

Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.

Michalski JM, Purdy JA, Winter K, Roach M 3rd, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD. Michalski JM, et al. Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):391-402. doi: 10.1016/s0360-3016(99)00443-5. Int J Radiat Oncol Biol Phys. 2000. PMID: 10661346 Clinical Trial.

3

Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406.

Michalski JM, Winter K, Purdy JA, Wilder R, Perez CA, Roach M, Parliament M, Pollack A, Markoe A, Harms WB, Sandler H, Cox JD. Michalski JM, et al. Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):75-80. doi: 10.1053/srao.2002.31378. Semin Radiat Oncol. 2002. PMID: 11917289 Clinical Trial.

4

Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).

Ryu JK, Winter K, Michalski JM, Purdy JA, Markoe AM, Earle JD, Perez CA, Roach M 3rd, Sandler HM, Pollack A, Cox JD. Ryu JK, et al. Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1036-46. doi: 10.1016/s0360-3016(02)03006-7. Int J Radiat Oncol Biol Phys. 2002. PMID: 12419429 Clinical Trial.

5

Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.

Michalski JM, Winter K, Purdy JA, Wilder RB, Perez CA, Roach M, Parliament MB, Pollack A, Markoe AM, Harms W, Sandler HM, Cox JD. Michalski JM, et al. Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):192-8. doi: 10.1016/s0360-3016(03)00072-5. Int J Radiat Oncol Biol Phys. 2003. PMID: 12694838

6

RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?

Valicenti RK, Winter K, Cox JD, Sandler HM, Bosch W, Vijayakumar S, Michalski J, Purdy J. Valicenti RK, et al. Among authors: michalski j. Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):614-20. doi: 10.1016/s0360-3016(03)00640-0. Int J Radiat Oncol Biol Phys. 2003. PMID: 14529764 Clinical Trial.

7

Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.

Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Kuban DA, et al. Among authors: michalski jm. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):915-28. doi: 10.1016/s0360-3016(03)00632-1. Int J Radiat Oncol Biol Phys. 2003. PMID: 14575822

8

Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.

Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Thames H, et al. Among authors: michalski j. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):929-43. doi: 10.1016/s0360-3016(03)00631-x. Int J Radiat Oncol Biol Phys. 2003. PMID: 14575823

9

Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.

Michalski JM, Winter K, Purdy JA, Perez CA, Ryu JK, Parliament MB, Valicenti RK, Roach M 3rd, Sandler HM, Markoe AM, Cox JD. Michalski JM, et al. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):735-42. doi: 10.1016/S0360-3016(03)01578-5. Int J Radiat Oncol Biol Phys. 2004. PMID: 14967428 Clinical Trial.

10

Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?

Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Kuban D, et al. Among authors: michalski j. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):409-14. doi: 10.1016/j.ijrobp.2004.05.021. Int J Radiat Oncol Biol Phys. 2005. PMID: 15667960

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

837 results

Search Page

Filters